Open AccessClinical case of the treatment of metastatic luminal breast cancer
Author(s) -
А. Ф. Насретдинов,
А. В. Султанбаев,
К. V. Menshikov,
Ш. И. Мусин,
Н. И. Султанбаева,
А. А. Измайлов,
R. Т. Ayupov
Publication year - 2021
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2021-20-160-166
Subject(s) - medicine , breast cancer , clinical trial , palbociclib , metastatic breast cancer , hormone therapy , oncology , cancer , hormone receptor , hormone , hormonal therapy , intensive care medicine
Hormone therapy currently open up the prospect of long-term, comfortable and relatively low-toxic treatment for patients with hormone receptor – positive advanced breast cancer. For a long time, the presence of visceral metastases prompted oncologists to abandon hormone therapy in favor of cytostatic agents. Now days, even in the presence of visceral metastases, clinical guidelines allow use of modern hormonal therapy in the absence of a visceral crisis. In particular, the so-called CDK 4/6 inhibitors, presented on the Russian market by drugs: palbociclib, ribociclib and abemacyclib, became the drugs that significantly improved the results of hormone therapy. Each of them has demonstrated its effectiveness in clinical trials; moreover, there are lots of clinical cases demonstrating the benefits of this therapy in real clinical practice. The article presents a clinical case of treatment of advanced hormone receptor-positive breast cancer. The effectiveness of treatment with CDK 4/6 inhibitors has been demonstrated, a comparatively analysed with the data obtained in the course of clinical trials. The analysis of the tactics of treatment of cytomegalovirus infection of the cornea during therapy with ribociclib was carried out.